BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
Delayed Nasdaq  -  05/26 04:00:00 pm EDT
0.6300 USD   -0.19%
04/21Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
AQ
04/21Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines
CI
04/19BROOKLYN IMMUNOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director Effective as of January 1, 2022

12/21/2021 | 04:30pm EDT

Brooklyn ImmunoTherapeutics, Inc. announced that Luba Greenwood notified the board of directors of her intention to resign as a director effective as of January 1, 2022. Ms. Greenwood’s decision to resign was not the result of any disagreement with on any matter relating to operations, policies or practices.


© S&P Capital IQ 2021
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
04/21Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Fac..
AQ
04/21Brooklyn ImmunoTherapeutics, Inc. Announces Establishment of New Research and Developme..
CI
04/19BROOKLYN IMMUNOTHERAPEUTICS, INC. : Changes in Registrant's Certifying Accountant, Financi..
AQ
04/18Brooklyn ImmunoTherapeutics Shares Slide After Company Reports Q4 Loss
MT
04/18Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Resul..
AQ
04/15BROOKLYN IMMUNOTHERAPEUTICS : Announces Fourth Quarter and Full Year 2021 Financial Result..
PU
04/15BROOKLYN IMMUNOTHERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulat..
AQ
04/15Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended..
CI
04/15BROOKLYN IMMUNOTHERAPEUTICS, INC. Management's Discussion and Analysis of Financial Co..
AQ
04/15Brooklyn ImmunoTherapeutics, Inc. Reports Earnings Results for the Full Year Ended Dece..
CI
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -27,7 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,19x
Yield 2022 -
Capitalization 36,2 M 36,2 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 10
Free-Float 58,1%
Chart BROOKLYN IMMUNOTHERAPEUTICS, INC.
Duration : Period :
Brooklyn ImmunoTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BROOKLYN IMMUNOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 0,63 $
Average target price 3,50 $
Spread / Average Target 456%
EPS Revisions
Managers and Directors
Howard J. Federoff President, Chief Executive Officer & Director
Sandra Gurrola Chief Financial Officer
Charles Reed Cherington Director
Kevin A. D'Amour Chief Scientific Officer
Roger Sidhu Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BROOKLYN IMMUNOTHERAPEUTICS, INC.-84.89%36
MODERNA, INC.-48.48%52 047
LONZA GROUP AG-28.07%42 228
IQVIA HOLDINGS INC.-27.93%38 488
SEAGEN INC.-11.73%25 121
ICON PUBLIC LIMITED COMPANY-31.56%17 232